These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23755169)

  • 1. Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice.
    Zetterqvist AV; Berglund LM; Blanco F; Garcia-Vaz E; Wigren M; Dunér P; Andersson AM; To F; Spegel P; Nilsson J; Bengtsson E; Gomez MF
    PLoS One; 2014; 8(6):e65020. PubMed ID: 23755169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia.
    Nilsson-Berglund LM; Zetterqvist AV; Nilsson-Ohman J; Sigvardsson M; González Bosc LV; Smith ML; Salehi A; Agardh E; Fredrikson GN; Agardh CD; Nilsson J; Wamhoff BR; Hultgårdh-Nilsson A; Gomez MF
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):218-24. PubMed ID: 19965778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor of activated T cells is activated in the endothelium of retinal microvessels in diabetic mice.
    Zetterqvist AV; Blanco F; Öhman J; Kotova O; Berglund LM; de Frutos Garcia S; Al-Naemi R; Wigren M; McGuire PG; Gonzalez Bosc LV; Gomez MF
    J Diabetes Res; 2015; 2015():428473. PubMed ID: 25918731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of NFAT Signaling Restores Microvascular Endothelial Function in Diabetic Mice.
    Garcia-Vaz E; McNeilly AD; Berglund LM; Ahmad A; Gallagher JR; Dutius Andersson AM; McCrimmon RJ; Zetterqvist AV; Gomez MF; Khan F
    Diabetes; 2020 Mar; 69(3):424-435. PubMed ID: 31806622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo inhibition of nuclear factor of activated T-cells leads to atherosclerotic plaque regression in IGF-II/LDLR
    Blanco F; Heinonen SE; Gurzeler E; Berglund LM; Dutius Andersson AM; Kotova O; Jönsson-Rylander AC; Ylä-Herttuala S; Gomez MF
    Diab Vasc Dis Res; 2018 Jul; 15(4):302-313. PubMed ID: 29499628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.
    Di Marco E; Gray SP; Chew P; Koulis C; Ziegler A; Szyndralewiez C; Touyz RM; Schmidt HH; Cooper ME; Slattery R; Jandeleit-Dahm KA
    Diabetologia; 2014 Mar; 57(3):633-42. PubMed ID: 24292634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.
    Recio C; Oguiza A; Lazaro I; Mallavia B; Egido J; Gomez-Guerrero C
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1953-60. PubMed ID: 25012131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-9 aggravates the development of atherosclerosis in ApoE-/- mice.
    Zhang W; Tang T; Nie D; Wen S; Jia C; Zhu Z; Xia N; Nie S; Zhou S; Jiao J; Dong W; Lv B; Xu T; Sun B; Lu Y; Li Y; Cheng L; Liao Y; Cheng X
    Cardiovasc Res; 2015 Jun; 106(3):453-64. PubMed ID: 25784693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.
    Barrett TJ; Distel E; Murphy AJ; Hu J; Garshick MS; Ogando Y; Liu J; Vaisar T; Heinecke JW; Berger JS; Goldberg IJ; Fisher EA
    Circulation; 2019 Oct; 140(14):1170-1184. PubMed ID: 31567014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
    Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
    Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
    Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced alpha-lipoic acid synthase gene expression exacerbates atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Yi X; Xu L; Hiller S; Kim HS; Maeda N
    Atherosclerosis; 2012 Jul; 223(1):137-43. PubMed ID: 22658261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Protective Effect of Interleukin-37 on Vascular Calcification and Atherosclerosis in Apolipoprotein E-Deficient Mice with Diabetes.
    Chai M; Ji Q; Zhang H; Zhou Y; Yang Q; Zhou Y; Guo G; Liu W; Han W; Yang L; Zhang L; Liang J; Liu Y; Shi D; Zhao Y
    J Interferon Cytokine Res; 2015 Jul; 35(7):530-9. PubMed ID: 25866993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Imaging of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Atherosclerotic Lesions in Diabetic and Non-diabetic ApoE
    Tekabe Y; Johnson LL; Rodriquez K; Li Q; Backer M; Backer JM
    Mol Imaging Biol; 2018 Feb; 20(1):85-93. PubMed ID: 28421362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Ta NN; Schuyler CA; Li Y; Lopes-Virella MF; Huang Y
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):157-66. PubMed ID: 21558879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.
    Calkin AC; Cooper ME; Jandeleit-Dahm KA; Allen TJ
    Diabetologia; 2006 Apr; 49(4):766-74. PubMed ID: 16463048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordinated augmentation of NFAT and NOD signaling mediates proliferative VSMC phenotype switch under hyperinsulinemia.
    Shiny A; Regin B; Mohan V; Balasubramanyam M
    Atherosclerosis; 2016 Mar; 246():257-66. PubMed ID: 26814423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
    Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism.
    McGraw AP; Bagley J; Chen WS; Galayda C; Nickerson H; Armani A; Caprio M; Carmeliet P; Jaffe IZ
    J Am Heart Assoc; 2013 Feb; 2(1):e000018. PubMed ID: 23525413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice.
    Zhang WJ; Wei H; Frei B
    Exp Biol Med (Maywood); 2010 May; 235(5):633-41. PubMed ID: 20463304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.